Application of smooth pursuit cognitive testing paradigms to clinical drug development

Abstract

The invention describes the process of applying smooth pursuit eye movement tests toward the detection of the efficacy and, or, toxicity of neuro-pharmaceutical compounds throughout the clinical drug development process. Several different paradigms in smooth pursuit tracking tests and several analysis methods and metrics may be used. Application of smooth pursuit tracking tests allows for a quantifiable measurement of a subject's cognitive behavior and function. This process provides a cost effective and objective test of efficacy of neuro-pharmaceutical drugs and increase the validity of the clinical drug development process.

Description

FIELD OF THE INVENTION

This invention relates to the clinical drug development process to apply the use of neuropsychological smooth pursuit tracking tests for providing quantifiable measure of cognitive behavior and function for detecting the efficacy of neuro-pharmaceutical compounds.

BACKGROUND OF THE INVENTION

In the field of neuroscience today there are a number of cognitive testing paradigms used by physicians, clinicians and individuals to assess one's cognitive performance.

The first and the most commonly used cognitive testing paradigm, especially the one that traces its origins furthest back in time, is the survey. The survey is a multipart questionnaire that is typically administered by a physician or a clinician. The set of questions in a survey, which may comprise of qualitative or quantitative questions, ask the individual taking the survey to evaluate oneself. Once the individual is finished taking the survey, the clinician or physician then evaluates the answers to the questions. The answers are evaluated in one of two ways. The answers are either subjectively evaluated by the physician or clinician, or entered into an algorithm to be processed to generate a score. The evaluation is then used to determine whether the cognitive level of performance of an individual meets a certain threshold or not to determine cognitive impairment.

The advantages to the survey are that it is portable and fairly easy to administer. In addition, the survey cognitive testing paradigm allows the test designer a great degree of freedom and flexibility in what questions to ask and the format of the test taker to answer those questions. However, there are downsides to surveys. One downside is that surveys are unfortunately relatively qualitative. Also, surveys are often open survey forms, where multiple choice and open-ended questions alike tend to convert into subjective answers. For instance, a test that asks, “How dizzy are you? Please quantify on a scale of one to ten” is not a truly quantitative test, but rather a subjective measurement of experience of the patient filling out the survey. A similar type of measurement error occurs if the question was asked in a multiple-choice format with answer choices of yes and no. Here, the patient then must select yes if they feel something, or select no if they don't feel dizzy or don't know what they might be assessing to feel. The survey paradigm also suffers when it relates to cognitive function because it presupposes a uniformly defined normative universally appreciated and semantically similar way of describing ailments from patient to patient.

Another common type of cognitive assessment is to study the reaction time of a patient in response to a test. Reaction time is typically used with recordings, and stopwatches or clocks. In recent time, reaction time tests area administered via tests on computers or over the Internet using keyboards or mice as input methods. Such reaction tests are conducted by presenting questions on the screen that the patient reacts to by pressing the input device. The data is then collected in the form of milliseconds of response time that the patient had to think and compute. This data is then aggregated and typically processed by methods such as average and standard deviation over the course of multiple trials in order to get a midline value or range of reaction time for a certain type of test.

Reaction time tests also attempt to analyze decision making by presenting a question that the patient must respond to make very quickly by pressing one or multiple types of stimuli. An example of such a reaction time test would be the following: the test involves the display of two different icons and the patient is asked to press the space bar only if one icon appears but not when the other icon appears. The result of this is that the reaction time test also measures the quality of the reaction with the decision, and not just the reaction time in general.

Unfortunately, reaction time tests have many disadvantages. Reaction time tests, while somewhat quantitative, suffer from low “test re-test reliability” and high degree of error induced by the environmental control. There are simply too many other variables at play. Also, the process of measuring reaction time needs to be iterated many times, often in the hundreds or thousands range, in order to produce a meaningful figure. The biggest problem with these tests however is that these tests are highly reliant on the patient's willingness or will to take the test. The resulting outcome then is more oftentimes a function of patient willingness to take a test and not the patient exhibiting the symptom or the phenomena that one is looking to measure in the first place.

A more modern cognitive testing paradigm is the balance test. The balance test paradigm may ask a patient to sit or stand on a ball, such as a balance ball, in some off-center form. With the use of cameras or measuring devices such as semiconductor components being placed on the patient, the system measures how stable the patient is to determine the cognitive ability associated with the brain circuit pathway for balancing.

The downfalls of balance tests are that balance based tests are quite noisy. The noise is because of several variables being at play in the process of measuring them, and the devices used to measure the variables, such as cameras, accelerometers and other forms of driverscalpic sensing, are simply not advanced enough to produce a reliable metric. Furthermore, the measurement of balance tends to be fairly binary, i.e. stable or unstable. Moreover, connecting the instability measurements to specific types of cognitive decline is quite difficult because disorientation can be caused by effects unrelated to cognitive ability such as a headache, a blockage in the ear canal and dizziness.

Neuroimaging technologies have also been used to assess cognitive performance. Neuroimaging technologies are generally broken into two different categories of testing. The first category of neuroimaging technologies includes those that analyze images, such as fMRI and CT scans. The second category of neuroimaging technologies includes those that analyze waveforms, which typically are EEG or MEG technologies.

The neuroimaging technologies that use imaging rely on an imaging system, which captures some form of metabolic or electric activity inside the brain. This activity is typically mapped in a topological way to the three-dimensional coordinates of the brain. There is typically a one to one mapping between the section of the brain with activity and the physical location of the brain. Typically slices, map or pictures of the brain are taken at various locations inside the brain, but the mechanism underlying those imaging technologies is capturing the metabolic rate of the neurons as they are activated by the brain in order to process signals. Metabolism typically takes the form of a consumption of glucose or sugars or some form of chemical in the brain that generates some kind of activity, such as a waveform of heat or electrical activity. This is a coarse grain way of assessing what part of the brain in general is consuming energy at any given time.

The second type of imaging relies on the analysis of the movement of liquid or fluid or the emission of electrical or magnetic signals in the brain. The waveform based cognitive neuroimaging technologies rely on surface based analysis, based on sensors that are placed on the skull on the outside of the head which read electrical or magnetic activity. As the sensors are positioned on the outside surface of the head, the depth in which they can measure activity in the brain is limited. Thus the sensors generally have a more difficult time measuring waveforms or activities inside the brain closer to the brain stem. However, as a very high level measure, the sensors can also generate an assessment of where the user's brain is active at any given time.

Neuroimaging technologies suffer a variety of problems, although to date they have been perhaps the most promising and eye opening about the relationship between the physical location of impairment with behavioral impairment or change. One of the problems is the problem of not knowing what variables to compare during the testing process. For example, it is unclear if the images should be compared from one patient to another patient, a patient to a population statistical average, or a patient to their baseline taken at some previous time. However, whether it is from patient to patient, from patient to a population statistical average, or from patient to himself or herself, there are too many variables to consider and cannot make anything more than generalizations about the conclusions of the patient's cognitive performance. Furthermore, both neuroimaging and their related signal analysis in the cognitive assessment paradigms suffer from the challenge of having noisy data. The high level of noise usually drowns out the signal that one would wish to analyze. On top of the noise from the devices and the surrounding environment, the background of mental activity is often difficult to filter out of the actual signal associated with the one being tested for and prevents doing any kind of meaningful analysis.

Another paradigm of promising cognitive assessment is by biomarkers, diagnostic tests or bioassays. This form of cognitive assessment generally relies on the breakdown of particles inside the brain via some kind of emission of particles from the cell from the neuron into the blood stream. As damaged cells emit byproducts of neuron structures into the blood stream, measuring the presence or availability of those breakdown byproducts can be used to determine if any cognitive damage has occurred in the brain and the severity of the damage. The challenge of these tests in general is that they tend to be invasive or require bodily fluid sampling. In addition, it is very difficult to correlate the results of the test with the precise location of the damage with just fluid sampling alone, such as blood or urine sampling. Therefore, at best this paradigm serves as a high level indicator of brain damage, but not the location of the damage.

The most promising of these neuro-diagnostic tests and cognitive evaluation test platforms is perhaps eye tracking. Eye tracking is used to look at the movements of the eyes in a response to a series of tests or stimuli that the patient must either follow or void or count or tally with their eyes. By measuring the fluidity, momentum and precision of the movement of the eyes as they track objects that are likewise moving or reacting on the screen, a more precise level of various cognitive functions can be determined. The distinction here is that the cognitive function is evaluated as opposed to the physical structure of the brain. This is promising because as one is measuring the physical structure of the brain, the measurement has very little correlation to the actual cognitive function.

Across all of these cognitive testing paradigms, there is a general set of problems such as the long length of time to administer the test, the time taken by the test taker and the test itself from start to finish, and the requirement of trained personnel and experts. Also, the cost of running these tests is very high, not to mention the cost for the administrator to not just run the test, but to be educated about the test.

It is important to note that various cognitive testing paradigms have been employed in the past in an attempt to be used in the process of drug development. However, these paradigms have suffered a number of drawbacks over the subject matter.

Cognitive Diseases and Disorders

As research continues into understanding cognitive function and cognitive functional deterioration with age, disease, or impairment to the physical brain, much has been discovered about the different types of neurological diseases and disorders that patients develop. At a very high level the diseases can be categorized into two broad categories. The first category includes those that have an impairment of attention, which are sometimes called neurological diseases because attention is thought to be a cognitive function. The second category of impairment includes those that can be referred to as a brain injury, such as those caused by a concussion or a traumatic brain injury. This is when physical neuron structures in the brain are sheared, distorted, pulled, stretched or broken structurally. Typically the sources of structural breakage are rapid impact movement, twisting, torqueing, or anything that might break tissues inside the brain.

Regardless of the category of cognitive disorder or diseases of the brain, the same can be said about all deteriorations of the brain, which is that at the current time it is difficult to classify and quantify the nature of the brain impairments. This is because the assessment metrics and measurements are relatively primitive and rudimentary in design, and are focused primarily on assessing the patient's self-diagnosis of state and cognitive functions. Thus, the use of surveys as described previously has been the dominant paradigm of interrogating a patient in assessing the severity of decline and function. Typically this relies on two core functions of the patient. One is the ability of the patient to self-describe the ailment. The other is the patient's ability to properly assign meaningful vocabulary to the ailment.

The following is a brief description of several common forms of cognitive impairment and cognitive decline today:

Beginning with Alzheimer's disease, this appears to be linked closely with the deterioration of short-term memory as well as in some cases medium to long-term memory. It is often accompanied with deterioration in attention span, and the ability for one to engage in the meta-process of focus.

Parkinson's disease is another disease studied commonly for its impairment in motor function, and the apparent introduction of the Parkinson's disease tremor, which appears as a series of motions and movements that do not appear to be in complete control of the conscious brain of the subject or patient.

Schizophrenia is accompanied by deterioration in the ability to maintain attention and focus over long durations of time as well as feelings of paranoia and delusion, as well as a disassociation between the body and the sense of mind and the self in the brain.

Epilepsy is a thought to be a form of a deterioration of the ability of the hemispheres to synchronize electrical pulses and signals and is sometimes accompanied with memory impairments and attention impairments.

Attention deficit disorder (ADD) is thought to be accompanied by a attention impairment in the absence of an obvious currently understood physical change in the brain or the structure of the brain as is readily seen in Alzheimer's disease, Parkinson's disease, schizophrenia and epilepsy patients, as well as attention deficit disorder (ADD) or attentional deficit hyperactivity disorder (ADHD) represent deteriorations or enhancements of the function of attention in a patient.

Insomnia is an inability to control the function of sleep or an inability to maintain a ready state of sleepiness.

Dementia is a broader term which is used to categorize a number of cognitive impairments, and so is not necessarily focused on a single specific or classified specific or class of impairments, but rather have been associated with a general set or cluster or category; among those is typically an impairment of attention.

Although traumatic brain injury is a description of cognitive structural damage in the brain it is most often associated with an inability to focus, especially the eyes, reduction in attention span and the accelerated development of symptoms exhibited in some of the preceding ailments. There does not appear to be a general set of symptoms of Traumatic Brain Injury or TBI, but rather if the brain is affected in a negative way, for instance, if that section of the brain exhibits damage, the function of that section of the brain then exhibits damage.

In a similarly ambiguous definition, post-traumatic stress disorder (PTSD) typically describes the relationship of cognitive decline with a specific event. In this case, specifically a traumatic event that has the potential to change the behavior of the patient in some way is measured. It is not thought that physical structural damage would occur when this PTSD is induced, but rather that parts of the brain are shut down because of the trauma or stress presented to the brain.

Drug Development Market

The field of drug development is categorized at a very high level with a framework that encompasses two very different philosophies of determining the efficacy of a substance and its expected impact on the human body.

On the one end, there is the pharmaceutical process, which is sometimes referred to as the large molecule drug development end of the drug marketplace where the effects of particles and substances are sought and are expected to have an effect on a biological system, specifically a human or a very close approximation with a human model. The process is characterized by mining a set of compounds or chemicals in order to discover whether they have an effect on a certain system in the human body. This is typically a time intensive and relatively primitive in approach. It is similar to the effect of lining up a series of candidates based on some hypothesis that it might be effective to test them and then assessing whether that outcome is positive, negative, neutral, etc.

At the other end of the spectrum is a type of drug development referred to as small particle drug development, which is also commonly called the biotechnology process. This development process is focused on developing a specific candidate molecule that will change or modify biochemical signaling or processing, such as inhibiting or increasing the production of specific protein compounds in the body as a result of a very close bottom up targeting of a very specific chemical pathway in the human body. This development process is characterized by a set of analytical techniques that rest heavily on computational modeling.

Both of these systems have existed for some time and have exhibited varying forms of success. They have tended to favor different types of biological systems, one performing better in some cases, whereas the other will excel at different types of diseases or ailments or biological systems. Thus these two approaches have coexisted in the drug development marketplace for some time.

Independent of how the drug is developed, there are common questions asked in the process of developing a drug. For instance, one question is whether the drug is toxic. Another question is to what degree or magnitude the drug works. Those two questions tend to be the dominant questions that drive the strategy of developing drugs. Other questions include what dosage or frequency of administration are ideal, and what interactions a drug might have when combined with other chemicals, foods, and conditions of the body.

The question of toxicity is typically measured on the basis of human response or animal model response. This process takes the form of administering a certain type of chemical or compound to a human or an animal model and seeing at what dosage the negative side effects begin to occur.

This process is far from scientific and typically results on qualitative measures of surveys; how do you feel, behavioral assessments including sluggishness, motion, swelling or very physical attributes like joint pain, swelling, and water retention, which are viewed as negative side effects. Some amount of the medication less than the onset of negative side effects is then targeted as the effective dose. However, the determination of the effective dose is also bounded by the incurrence of positive effects of the drug on the system that it wishes to target.

The question of measuring efficacy is a slightly more complex one and requires typically longer periods of time for observation to assess whether the drugs are having the desired performance or not. The measurement of efficacy is complex and difficult because the attributes of cognitive function and behavior exist in a space that is not easily quantifiable with current readily available metrics. Currently the quantification of behavioral or cognitive functional enhancements must be made slowly over an extended period of time and is predominantly driven by qualitative metrics.

In the drug development process, drug candidates that are expected to have positive effects in treating a negative ailment or disease are typically staged in a series of three phases: preclinical stage, post clinical stage and premarket stage. The objective of staging the clinical drug development process in this manner is to mitigate risk or reduce expense by staging progressively increasing amounts of money for funding to assess the viability and performance of a specific drug candidate.

In the first phase of early preclinical stages, animal models are used to triage whether the drug candidate would be expected to have an effect in humans.

In the second phase of the drug development process, or the post clinical stage, the toxicity of the drug candidate is assessed.

In the third phase of the drug development process, or the premarket stage, a small candidate group of patients with ailments is given the drug candidate in order to determine if the cognitive situation or the ailment improves. If in the event that it does, a second trial is run with even more patients, and if that continues to improve the number of patients increases until a sufficient amount of data has been made to make a case between the relevant government agencies to make the case that the drug should be made available for sale on the market.

The clinical pipeline process for developing drugs that affect the cognitive function and behavior is currently insufficient and mismanaged. This can be attributed to two main problems.

One problem is the current lack of availability of readily deployable technologies for the measurement of cognitive function in order to quantify whether a cognitive impairment or improvement occurs. Due to the lack of quantitative technology, the traditional tools of the analytical researchers, namely statistical and analysis and behavioral quantification, are lacking and not available. The implication of this is that there is a tremendous risk that drugs that might have had a statistically significant effect in improving or detecting the process of impairment of cognitive functional decline may be cutoff to early. The inverse of this problem is that the process of applying luck or encouraging positive chance through the drug development process results in unnecessarily lengthened pipeline processes and higher research and development costs. Thus, if a technology were available to that detect and assess cognitive function in a quantified way, it could be applied to lower the research and development costs.

The other problem is that the drug development process has low accuracy. When a benefit is detected but cannot be quantified, it is difficult to benchmark or relate that benefit to a similar benefit exhibited by another patient without being able to apply a standard normalized consistent testing process to both of those patients. Even a baseline versus change paradigm would benefit if the cognitive function of a patient were quantified, rather than it being qualitatively evaluated. Similarly, the “test-retest reliability” and the error interval of a quantitative paradigm would be easier to determine than that of a qualitative paradigm. With such a quantitative paradigm, a high “test-retest reliability” and low error interval would better instill trust and a degree of confidence in the results.

It has been reported that eye tracking and fixation has been utilized in evaluating pharmaceuticals, but only as far as measuring its effect on the eyes to fixate on an immovable dot or icon. In this paper, “Preclinical assessment of CNS drug action using eye movements in mice,” by Hugh Cahill, Amir Rattner and Jeremy Nathans, Journal of Clinical Investigation, Vol. 121, No. 9, September 2011, mice were caused to stare at a dot and the jitter in their gaze direction was quantified after compound injection.

However, fixation is not a smooth pursuit technology and is less accurate in establishing a drug reaction baseline.

SUMMARY OF THE INVENTION

It has been found that smooth pursuit tracking, whether eye tracking or mechanical tracking, can be used in drug screening to accurately evaluate toxicity and efficacy. This is because smooth pursuit eye tracking involves the autonomic system and is thought to be a reflex process in the central nervous system. On the other hand, the Cahill fixation involves a conscious thought process to not move one's eye, which invariably causes a hand off between a portion of the brain involved in thought process and a portion of the brain involved in autonomic cognitive system. Another difference between fixation and smooth pursuit is that smooth pursuit involves more complex pathways throughout the brain than fixation.

Thus, what is provided is an early drug screening system that uses smooth pursuit tracking to determine the efficacy and toxicity of drugs. Rather than using prior drug screening procedures, a quick and accurate prediction of drug efficacy and toxicity can be obtained by smooth pursuit tracking techniques. Smooth pursuit tracking involves the smooth curvilinear movement of an icon, dot or target on a screen and having an individual track the position of the dot. The degree to which the individual tracks the dot determines cognitive performance, and it is a change in cognitive performance, which if measured precisely, measures the effect of the drug on the body. Such cognitive performance can be measured using eye tracking in which the motion of the eye is captured when the individual tries to track the dot. Cognitive performance can be measured by mechanical tracking in which an individual uses his finger or other body part's motion to track an on-screen moving dot. Regardless of the smooth pursuit technique for measuring cognitive ability, it is the measure of this cognitive ability that provides for rapid drug efficacy and toxicity testing.

More particularly it has been found that a new smooth pursuit eye tracker technique yields precise quantitative results that makes smooth pursuit eye tracking ideal for rapid drug testing. The statistically significant quantitative results provided by the new eye tracking technique are the result of excluding the outside environment around the head, and using algorithms which remove outlying data as well as specialized standard deviation techniques, and in one embodiment, the use of peak performance detection.

This invention thus contemplates the use of eye tracking coupled with a paradigm of smooth pursuit tracking as a platform diagnostic to be applied throughout the clinical drug development process. Rather than administering a drug and observing any untoward effects that take hours if not days to manifest, in the subject invention drug efficacy and/or toxicity can be rapidly ascertained using smooth pursuit eye tracking. Since most drugs affect cognitive processes, accurately measuring cognitive ability using smooth pursuit techniques as a drug is administered provides early assessment of toxicity and efficacy. If there is no change in cognitive ability, then no matter what the particular drug is supposed to do, if the brain is not affected, the drug cannot be efficacious.

Thus, as a first cut, the target drug must at least have an effect on cognitive ability, with the subject smooth pursuit techniques providing a basic filtering function to filter out drugs that have no chance of working.

Secondly, if there is change in brain function one can devise a series of smooth pursuit tests to test for a particular response.

More particularly in one embodiment an eye tracking diagnostic procedure is used to measure and assess cognitive change in cognitive function or behavior, negative or positive, in response to the drug compounds. The analysis can be performed by using highly accurate eye trackers of the subject invention or by using mechanical motion of the extremities to track a moving on-screen dot or icon driven to establish smooth motion. The accurate and highly quantifiable test can also be performed by a hybrid of mechanical and optical testing by mechanical manipulation of a finger or stylus to match dot movement as the eyes track the moving icon on a screen.

The smooth pursuit test used in one embodiment of the invention can be driving the on-screen icon to execute a circular smooth pursuit path, a sinusoidal smooth pursuit path or any curvilinear smooth pursuit path. The measurement can involve a number of different indices of the ability of the test subjects' eyes to track the on-screen icon including anticipatory timing in terms of how well the test subject anticipates icon movement, regularity of the person's ability to track the onscreen icon, variability of any of the previous test results, predictability of the test results as well as other methods.

For purposes of the subject invention anticipatory timing means measuring the lead or lag time of an individual's response to tracking a smooth pursuit target icon to anticipate the future position of the icon.

Variability means the distance error as the individual follows the target icon.

Regularity means the consistency of any smooth pursuit tracking measurement, with maximum consistency meaning that the errors over time are the same.

Predictability means the degree to which the test subject's past input and errors can predict the next input.

Peak performance means increasing the maximum performance that the test subject exhibits during the duration of the test.

There are thus a number of different metrics by which one can quantify and assess changes in cognitive behavior that are described in U.S. patent application Ser. No. 13/506,840 filed May 18, 2012 and Ser. No. 13/507,991 filed Aug. 10, 2012. Data analysis proceeds as described in these patent applications and will be described herein. Specifically the testing process and analytical process must exclude as much noise as possible through data cleansing methods such as normalization and noise infiltration detection. It is important that data cleansing occurs before quantifying and assessing changes in cognitive behavior via score calculation.

Smooth pursuit eye-tracking tests should be administered during clinical trials on a patient-by-patient basis and at the beginning of the trial to collect a baseline against which testing results can be compared. The test should also be administered at various times under a mix of environmental conditions, metabolic conditions, and times of day to vary conditions of fatigue. Each of these conditions have an effect on smooth pursuit testing in general, with the magnitude of effects of these conditions cancelled or at the very least quantified to increase the accuracy and precision of the analysis. The test should also be administered on a regular basis as prescribed by a statistician looking for specific outcomes and effects, especially in a method consistent with the general statistical strategy of the current clinical phase.

The cognitive testing of the smooth pursuit variety is administered, and at the conclusion of the test the scores are evaluated. If the test score is in any way inconclusive a follow up phase may be necessary in order to quantify efficacy and validity, and to establish the lack of toxicity if such is the case.

Unlike other cognitive testing paradigms that carry significant expense and that can only be used at the beginning and end of the clinical trial, the relatively low cost of the smooth pursuit eye tracking and mechanical tracking as well as the hybrid test, mean that cognitive evaluation can be used throughout the clinical process and throughout the phases of the drug development process. This in turn increases the statistical validity or significance of this data, heightening the determination of the efficacy of a drug.

In addition, another advantage of the subject invention is that the cognitive pathway accessed with this test is complex, i.e. one requiring the simultaneous coordination of a number of different sections of the brain at once to perform a relatively straightforward, and simple mechanical or visual task. In either case, the test task is mechanical because the eyes are controlled by muscles and are positioned by the brain as they move around and refocus and relocate on the other screen icons. The test can also be accompanied other forms of mechanical smooth pursuit tracking involving the hands or other extremities such as feet, core, body, legs, arms, fingers or head. By doing so, due to the coordination cost in the brain of coordinating an anticipatory action as well as the muscle movement in order to control the fine movement of a human body part that is attempting to follow a target dot moving in a smooth path, the circuit in the brain that correlates to this activity is further stressed, and involves more complex and variable regions of the brain when using mechanical tracking. This complex test is advantageous because it involves more areas of the brain and thus is a more accurate test of any cognitive change to the brain.

The test subject's relative positioning of a point of gaze on a dot that one is attempting to follow, controlled by the test, creates a number of readily measurable and analyzable quantitative metrics of patient cognitive performance. At one end of the spectrum a very simple metric is a simple analysis of the lead/lag or steadiness of the eye tracking result. At the other end of the spectrum, metrics of variability, reliability and consistency can be applied in order to assess the degree to which the user maintains a consistent response relative to the moving target. The diversity of these metrics is advantageous because they confer a number of variables that can be analyzed by the testing paradigm. For instance, anticipatory timing involves how a person's gaze leads or lags a moving target can be measured and quantified independent of mechanical jitter.

Moreover, while anticipatory timing involved in eye tracking is useful to assess drug efficacy for a number of diseases, it has been found that mechanical smooth pursuit tracking can catch and measure effects associated with epilepsy and Alzheimer's disease independent from schizophrenia or Parkinson's disease. Likewise, mechanical smooth pursuit tracking can measure the effects of anxiety, anticipation or the stimulation effects of stimulant compounds by measuring mechanical jitteriness, eye jitteriness or involuntary extremity movement while tracking a test target or icon moved smoothly about a curvilinear path.

A simple testing paradigm such as smooth pursuit can therefore be applied across clinical processes in order to measure a number of different analytical impairments quantifiably changed from a baseline before and after the administration of a therapeutic compound. Smooth pursuit testing can also assist in the detection of cognitive performance changes in order to catch both performance enhancement, efficacy, as well as deterioration of cognitive function associated with toxicity of a compound, as it passes through the clinical drug development pipeline process.

Other advantages include the fact that smooth pursuit eye tracking or mechanical tracking can be administered in a portable environment. With mechanical smooth pursuit, the hardware requirements for the test are merely an input source, which can be a trackball, a mouse or a touch screen, and the output source is merely a screen, such as that of a laptop or tablet computer. The test can even be administered on a projector, meaning that the test provides a reliable metric of smooth pursuit, ability and testing in a relatively portable environment.

In summary, smooth pursuit cognitive testing can be used in clinical drug development to ascertain the effect of a particular drug or compound on the cognitive function of a test subject, with the smooth pursuit cognitive testing including either eye tracking, mechanical tracking or a combination of both.

BRIEF DESCRIPTION OF DRAWINGS

These and other features of the subject invention will be better understood in connection with the detailed description in conjunction with the drawings of which:

FIG. 1 is a diagrammatic illustration of an enclosure and mask for use in a desktop opto-cognitive device for cognitive assessment used for a clinical drug evaluation and development;

FIG. 2 is a diagrammatic illustration of the enclosure of FIG. 1, illustrating an individual having his or her face pressed to a mask which positions the eyes of the individual with respect to the screen of a laptop contained within the enclosure, thus to establish not only a fixed distance of the eyes to the screen but also that the plane of the screen is parallel to the plane across the individual's eyes such that the line of sight from the eyes to the screen is perpendicular to the plane of the screen;

FIG. 3 is a diagrammatic illustration of a mask usable for the enclosure of FIG. 1, illustrating apertures through which cameras are adapted to protrude to measure pupil position and thus eye gaze direction;

FIG. 4 is a diagrammatic illustration of the mask of FIG. 3 showing the mask-mounted cameras along with a processor, and a gaze direction and impairment calculation module for measuring cognitive function;

FIG. 5 is a diagrammatic illustration of the enclosure of FIG. 2 illustrating the distance between the eyes and the screen of the laptop contained within the enclosure;

FIG. 6 is a diagrammatic illustration of the utilization of handholds to either side of the enclosure of FIG. 1 to permit the individual utilizing the machine to press his face against the mask, with the individual braced utilizing his elbows against a table on which the enclosure rests;

FIG. 7 is a diagrammatic illustration of the utilization of the handhold on the side of the subject enclosure in which the individual utilizing the machine can press his face to the mask with his hands gripping the handle by pushing upward inside the handhold with the thumb and grasping down the enclosure from the top with the other fingers to stabilize his face against the mask;

FIG. 8 is a diagrammatic illustration that the mask of FIGS. 1 through 7 maintains the line of sight from the eyes to the screen of the computing device housed inside the enclosure at 90 degrees to the plane of the screen, thereby to enable an accurate gaze direction measurement;

FIG. 9 is a diagrammatic illustration of the clam shell type construction of one embodiment of the enclosure of FIG. 1, illustrating a computing device supported on the base of a lower clam shell, with the screen of the computing device being supported at the appropriate couple and orientation on ribs extending from the clam shell base, with the pivot point for the clam shells being sufficiently forward so as to minimize the space required for the device;

FIG. 10 is a flow chart showing one algorithm for measuring cognitive function using the desktop system;

FIG. 11 is a flow chart showing the subject system for determining drug efficacy or toxicity; and

FIG. 12 is a detailed flow chart of one embodiment of the subject invention showing a precision method for determining drug efficacy or toxicity.

DETAILED DESCRIPTION OF DRAWINGS

Prior to describing the subject invention, one convenient and inexpensive desk top unit for performing smooth pursuit eye tracking having the requisite precision is now described.

Precision Smooth Pursuit Eye Tracking Using a Desktop Unit

Referring now to FIG. 1, a desktop based opto-cognitive device 10 is provided with an enclosure 12 that has a mask 13 on its proximal face to which an individual taking a cognitive test is asked to press his or her face. It will be noted that the enclosure includes an integral angled handhold portion 16 as well as a horizontally orientated integral handhold portion 18, which is usable by the individual taking the test to press his or her face into mask 14 when the enclosure is supported on a pedestal at eye level. The enclosure also has a slit 20 to enable cabling 22 to pass from the outside of the enclosure to the inside of the enclosure to attach to an internally carried screen of a computing device, such as a laptop, personal computer or a tablet device.

As can be seen mask 14 includes cameras 24 located below the nose bridge of the mask with the camera and pointed towards the eyes of an individual taking the cognitive test to measure cognitive performance. Cognitive performance is ascertained by measuring gaze detection by detecting the position of the individual's pupils as they trail a moving dot on the screen.

Referring now to FIG. 2, enclosure 10 is provided in one embodiment with a laptop generally indicated by reference character 30 having a base 32, which rests on a support rib 34 at the base of the enclosure 12. The angled screen 36 of laptop 30 resting on a rib 38 attached to the back wall 30 of enclosure 12 to support the screen not only in its angled orientation with respect to its own base, but also, as will be discussed hereinafter to provide a plane for the screen that can be maintained perpendicular to a line from the individual's eyes to the screen, here shown in dotted outline at 42. The line of sight from the individual to the screen is indicated by arrows 44 to show that the plane of the eyes of the individual is maintained parallel to plane of the screen.

Also shown are handles 16 and 18, which in one embodiment are indents into the surface of the enclosure as illustrated in FIG. 1.

Referring now to FIG. 3, mask 14 is shown to have an elastic rubberized mask material 50 which has a nose bridge 52 and cheeks support sides 54 as well as a forehead supporting portion 56 all of which forming a type of goggle. However, rather than being head worn, the goggles are mounted to the subject enclosure as for instance through bolt holes 58.

Also shown in this figure are apertures 60 which are adapted to house cameras pointing up towards the eyes of an individual when the individual has his head pressed to the mask, the purpose of which are to detect pupil position and thus gaze direction of the individual taking the cognitive test. Here it is to be noted that since the individual's head is immobilized with respect to the screen, a rather inexpensive single camera can be used to detect pupil position, as opposed to the rather 80 plus treated cameras used to detect gaze direction using glint detection and iris position.

Mask 14 has a number of features that make it universal and capable of fitting to any adult face, regardless of ethnicity or gender to provide a fixed distance between the eyes and the screen, and also between the eyes and the light sources used to provide the glints.

First, the mask is made from a compound foam that is non-compressible, yet comfortable. In one embodiment the foam is a polyurethane foam model PG 250 made by Spectrum Plastics Group of Westminster Colo., with the foam having a 55 shore hardness. The shape of the mask was designed by taking an average of reported face measurements across the population demographic in the 90% percentile between the ages of 8 and 20, and thus allows for a universal fit.

Secondly, the curvature of the forehead-contacting portion of mask 14 has a horizontal curvature of a radius of 79 mm at the bottom, closer to the eyes, and narrows to the top of the forehead of the mask, with a vertical curvature of a radius of 107 mm. The forehead-contacting portion of mask 14 is 165 mm wide at the bottom and 155 mm wide at the top with such measurements used to accommodate a wide variety of forehead widths and shapes.

Thirdly, the nose cutout has a nose depth of 60 mm and nose width of 90 mm, designed to accommodate even the longest and widest of noses.

Finally, the portion of the mask that engages the cheekbones was sized to give the IR LEDs enough depth in front of the eyes. Note that the cheekbone of the mask refers to a narrow horizontal cheekbone plate.

The above establishes a predetermined distance between the IR LEDs and respective eyeballs so that this distance is the same for all faces.

The mask when properly configured properly contacts the forehead and the cheekbones and creates a light tight barrier to outside light so that the mask surrounds the face with a light-tight seal. The curvature of the mask horizontally across the eye portion has a radius of 277 mm and a width of 200 mm, which assists with this light-tight seal.

As mentioned above, the design for the universal eye mask shape is concentrated on three key face areas, namely the cheekbones, the nose bridge and the forehead. These three key face areas are chosen as a pinpoint because they are the areas of the face that have the least fat deposit and variations in fat deposits on one's face is the main cause for variation from one adult face to another. The result is the facemask curvature tightly hugs the cheekbones, forehead and sides of the face to create a tight barrier, which blocks outside light from entering the enclosure of the device.

It is a feature of the desktop unit that with a computing device such as a standard laptop placed on the ribs is shown in FIG. 2, the individual's eyes are no less than 38 centimeters from the laptop screen, nor more than 42 centimeters.

Referring to FIG. 4, mask 14 of FIG. 3 is shown in which like elements carry like reference characters and in which relatively inexpensive cameras 62 can be mounted into the orifices of 60 of FIG. 3 such that the cameras point upwardly towards an individual's eyes when the individual's face is pressed to the mask. Also shown are IR LEDs 64, the purpose of which is to shine a tangential light onto the eye so as to pop out the position of the pupil while at the same time illuminating the remaining part of the eye which appears white as opposed to the dark pupil.

When a moving dot 70 is placed on a computer screen 72 and is moved for instance as illustrated by dotted line 74, this movement is reflected in a change in the gaze direction of the individual taking the test. In order to obtain the gaze direction processor 76 within laptop 78 is utilized, with the output of the cameras as illustrated at 80 to detect gaze direction as illustrated at 82 in terms of the position of the pupil as detected by cameras 62. However, as illustrated at 84 cognitive abilities, or in fact cognitive impairment, may be ascertained in terms of the ability of the eye to track dot 70 as it moves. Also as illustrated in FIG. 4 the results of the cognitive impairment calculation may be displayed separately by a display 90. How gaze direction is detected in terms of pupil position measurement is as follows.

The processor and processing stage of calculation takes as an input the image of the eye and especially the dark pupil that is generated by the cameras and the infrared setup imbedded in the lower part of the face mask. The picture data is represented in pixels and the format can be anything from a raw picture to a compressed picture. The data input is specifically bounded in rectangular format such that the coordinates and position of the dark pupil appear roughly in the middle of the picture. The infrared LED illuminates the surface of the eye and also reflects into the dark pupil but not out, causing the dark pupil effect. The dark pupil effect is known in the literature and is described in the prior art as a method of eye tracking that is distinct from light pupil where the infrared LED is shown directly into the eye such that it bounces back out and illuminates itself in the form of white infrared light.

Once the pictures are generated by the cameras, these pictures are then stored to a data structure, which usually takes the form of a compressed movie or series/sequence of images. These images are stored to disk, or memory or random access memory for access by the processor and the software running on the processor.

The processor then performs a set of processing stages whereby it filters out the picture to determine where the dark pupil is in the picture. This is typically represented by a circular form of dark pixels with a hard circular ellipse edge. The ellipse edge is usually adjacent to the iris, which is either lighter colored or at least a greyer scale. In any event it is not dark or black, like the center of the pupil. Once the dark pupil pixel filter is applied, there is usually one large patch of dark pixels but also several smaller areas of dark pixels caused by for instance darkness of the eyelashes or clusters or discolorations on the surface of the eye or iris. This leads to a next stage of noise filtration where only larger sequential, continuous regions of dark pixels are identified, the largest of which is assumed to be the dark pupil.

At this point it is important to note that traditional advanced eye tracking that uses corneal reflection could be used to further define gaze direction. In this technology a byproduct of the infrared LED shown on the surface of the pupil is described in the prior art as a source of additional precision in the analysis of pupil position and location.

However, because the environment is sufficiently controlled in the desktop unit, this is not a necessary step. This is because one does not assume that the eye is moving significantly to the right or the left, and as a result one need not calculate gaze by cancelling out the effect of the head direction relative to the eye position. Instead, because the face mask fixes the head position toward the front, facing the screen, one can assume that the gaze is also in that direction and therefore one can skip the calculation of gaze utilizing corneal reflection. The circular shape of the ellipse that represents the dark pupil is then passed to a processing stage that applies an ellipse fit function onto the eye.

The state of processing for the desktop unit that calculates eye tracking parameters and variables off of two cameras and infrared lights shined onto the eye involves camera and infrared lights set up and configured on the front of the mask of the desktop eye tracking system.

After the dark pupil extreme positions are calculated, the algorithm finds the largest continuous region of ellipse parameterization and uses this as the estimated center point for the dark pupil. This dark pupil is then converted into a time stamp and dark pupil image data location, which is then passed to the next stage of the processing algorithm. The next stage of the processing algorithm takes the dark pupil data, runs the ellipse fit over it and uses the ellipse fit in order to generate the centroid of the ellipse in terms of x and y position as well as the time stamp, referred to herein as x, y and t for the names for the variables that are used in the algorithm and calculations. The pupil position is generated containing all of the x, y and t values for the frames and the centroids of the ellipses. Those are represented in a long table or vector, where each row of the table contains one triplet set of x, y and t for each eye for the left eye and the right eye. This means that there is an x, y pair for the left eye and an x, y pair for the right eye at a single time stamp shared across both. That time stamp refers to the two images, one that is the left eye and one that is the right eye.

The next stage is a data processing stage, which runs through the table of x and y positions and eliminates any points where the algorithm outputs suspicious results. For instance, if a blink occurred or if the eye tracker briefly lost track of the dark pupils of the left or the right eye or perhaps both eyes at the same time, the algorithm will cancel this out and insert nulls or no data, NA's or zeros in place of the data that previously was x and y data. In addition, simplification in calculation can be made assuming that the eyes do not move faster than a certain velocity in the frame rate the eye should not jump more than a certain amount in any given direction between consecutive frames. Thus if the eye is seen to move larger than an expected range, it is safe to say the algorithm or the inbound image contained a source of error or was corrupted, or that the user introduced some environmental error which overwhelmed the signal. In any of these events, the data is canceled out.

The resulting data post filtering is now a sequence of data points referring to x and y for the left eye and the right eye as well as a time stamp for the pairs. Thus the centroid of the dark pupil defines the gaze direction and it is this gaze direction which establishes lead and lag times as the dot moves on the screen. Note, filtration techniques of data files are described in the prior art.

The x, y, time stamp and optionally the height and width of the ellipse for each of the left and right eye data as reflected in a table is then converted and brought to the algorithmic processing stage where the eye data is assessed to determine whether it is considered valid and appropriate given the assumptions of the test taking environment. For instance, the left and the right eye should be roughly in the same position with respect to each other and that people will not be moving cross-eyed randomly.

It has been found, contrary to glint position measuring systems, that the accuracy in establishing gaze direction is significantly higher when the target, in this case the pupil, is large. It will be appreciated that the size or extent of the glint is two orders of magnitude smaller by area versus the pupil. Therefore assuming the same pixel density, the larger pupil feature centroid is computed with greater accuracy. This being the case one can achieve exceptional accuracy without glint tracking by detecting the centroid of the pupil.

More particularly, the number of pixels that define a glint can be as little as four, whereas the number of pixels which define a pupil can be orders of magnitude more. The subject system ignores the problem of the accuracy associated for instance four pixels and rather achieves a greater accuracy when considering the vast larger number of pixels associated with a pupil. Moreover, calculation of pupil position may be done in a number of different ways to reduce position error even further.

There are a number of ways in which cognitive impairment can be measured through eye tracking, most notably in the lag time or lead time of the eye as its seeks to track moving dot 70, this lag time or lead time is referred to as anticipatory timing.

Not only are the lag time and lead times indicative of cognitive ability, variations in anticipatory timing is a sensitive measurement of cognitive ability.

The net result is that one can utilize any of the number of techniques to measure cognitive ability in terms of gaze direction measurement and all such cognitive ability measurements are contemplated.

It will be noted that in a measurement system that utilizes the previously described enclosure, there is absolutely no need for calibration of the system and that one need not have a separate calculation for use by a test administrator precisely because no calibration is necessary.

Referring now to FIG. 5, it is noted that the distance of the eyes of individual 42 to screen 36 as illustrated by arrow 94 is to be no less than 38 centimeters and no more than 42 centimeters for the reasons discussed above. Thus, by pressing the individual's face to mask 14 all critical measurement parameters are established for accurate cognitive assessments.

Referring now to FIG. 6, the ability of the individual 42 to position his face relative to mask 14 and keep it immobilized with respect to the enclosure is made easy through the utilization of handholds 16 and 18 on the exterior surface of enclosure 12. Here it can be seen that individual 42 has an elbow 96 placed on a table 98 which forms an elbow support such that when the individual's hand 100 grasping handhold 16 moves in the direction of arrow 102 the face of the individual 42 is moved in direction of arrow 104.

It will be appreciated that the accuracy of the subject system is critically due to the ability to immobilize the head of the test taking individual, both with respect to the enclosure and mask and with respect therefore to the internally carried laptop computer screen or other screen of a computing device that is provided.

By providing an easy method for the individual taking the test to clamp his face to the mask one provides for accurate cognitive ability measurement with a desktop-based opto-cognitive device and system.

It will be noted that an individual seated in front of the subject desktop enclosure may have a tendency to move his or her head during a test that swings the test.

However, by providing an ergonomically designed enclosure, mask and handhold combination, the individual if seated in front of the enclosure can brace himself or herself utilizing the elbow based method illustrated in FIG. 6.

Referring to FIG. 7, if individual 42 is standing in front of the machine supported at eye height, the individual can nonetheless clamp his face to mask 14 utilizing handle 18 by wrapping the fingers of his hand 100 over the top portion 106 of enclosure 12 as illustrated by arrow 108. Here the individual clasps handhold 18 and moves his handhold in the direction of arrow 110 to move his head again as illustrated by arrow 104 towards mask 14. Since the individual does not have the ability to support his elbow as illustrated in FIG. 6, he can nonetheless take a test in a standing position with his face pressed to mask 14 through the gripping mechanism described in this figure.

Referring now to FIG. 8, what is shown is that the eyes of individual 42, here shown at 120 and 122 have a line of sight direction illustrated at 124 that is orthogonal to the plane of computer screen 36 as illustrated by the 90-degree angles. It will be appreciated that when the head of individual 42 is clamped in the position illustrated in FIG. 8, the plane illustrated by dotted line 126 of eyes 120 and 122 is parallel to the plane of plane 36.

As mentioned before, the importance of such of arrangement is that no calibration is necessary to determine gaze direction due to the fixed placement of the individual's head with respect to the screen, with the sight lines normal to the screen.

Referring to FIG. 9, in which like elements of FIGS. 2 and 9 have like reference characters, what can be seen is that in one embodiment the enclosure is a hinged clam shell enclosure having a bottom base 130 and a top clam shell portion 140 hinged together at hinge pin 142. Here a laptop having a base portion 32 and a hinged screen portion 36 are supported by the base ribs 32 as described hereinabove. Likewise the computer screen 36 of the laptop is supported by the aforementioned ribs 38 such that not only is the angle of the screen with respect to the laptop base maintained, the plane of the screen 36 is determined by the plane of ribs 38 such that its plane is referenced to the plane of face plate 146 of top clam shell 140 that carries mask 14. Here slit structure 20 permits passage of tables 22 through the enclosure as shown.

It will be seen that with this pivoted clam shell structure, a laptop or other computing device can be easily positioned within enclosure 12, with the position of the pivot point as well as the configuration of the sidewalls 146 of the upper clam shell minimizing the amount of area that is necessary for the support of the subject device such that when the clam shell is opened as illustrated by double ended arrow 150 there is sufficient clearance for a desktop device, without having to leave a large amount of space to permit the opening of the clam shell.

Referring now to FIG. 10, in one embodiment for the precision measurement of cognitive awareness, as seen at 150 one initially installs a desktop device and sets it up as illustrated at 152 first by opening the top shell of the device is illustrated at 154 and by placing the computing device inside the disclosure as illustrated at 156, whereupon one installs and runs tests software as illustrated at 158. Thereafter a test is run as illustrated at 160 by presenting a moving target which is a dot or icon 162 on a screen of the computing device. This moving target is time stamped at 164 utilizing a clock 166 with simulated analog motion 168 used to generate a smooth pursuit path 170 that is utilized to drive the motion of the icon on the screen. The smooth pursuit path is in one embodiment a curvilinear path 172. Note clock 166 coupled to the simulated analog motion unit 168 as illustrated at 174 with or without a performance feedback.

When the test is run, a data file is generated at 180 from a data file 182 that is in turn time stamped at 184 utilizing a clock 186. Data file 182 stores the X,Y location of the centroid location of the pupil 188. Also stored is a validity marker 190 that a frame is valid or invalid derived from the output of pass/fail and filtration operation 192. The pupil position measurements as illustrated at 194 utilized to derive the X,Y centroid of location of the pupil. These pupil position measurements use pupil eye tracking 196 which incorporates an ellipse-fit algorithm 198 and edge detection calculations 190, thus to accurately determine gaze direction through the X,Y centroid location of the pupil. Having the generated data file 180, one utilizes a data filtration step 200 that eliminates blinks, saccades and head drift as illustrated 202.

Having filtered the data, the next step is gaze transformation 204 in which as illustrated at 206, one transforms pupil centroid data to where each eye is looking on the screen at each time stamp. Gaze direction is ascertained in the traditional manner as described above.

After having transformed the gaze to provide a gaze direction as illustrated, at 208 one compares the left eye and the right eye gaze location with target location at each time stamp. Eye gaze transformation data is available for this process at 210 having been time stamped at 212 and having been derived from an X, Y pixel location transformed into absolute values at 214.

Thereafter a table of cumulative absolute deviations is derived at 216 utilizing X and Y differences for individual deviations over time at different time stamps as illustrated at 218.

Then, the longest and cleanest set of data is isolated at 220 and cognitive processing, namely data analysis, is performed at 222. The cognitive processing includes metrics such as ascertaining anticipatory timing 224, variability 226, regularity 228 and peak performance 230, after which, depending on the metric utilized, the results are displayed at 232 either as a score or some other result representation.

The above processing provides an inordinate amount of processing to filter out outlying data, blinks, saccades, head drift and other environmental factors, such that when gaze direction is calculated all the extraneous effects of noise are eliminated from the gaze direction data. Environmental and head position noise has already been limited by the use of the subject desktop device to eliminate ambient light from getting into the system and to minimize the effect of head movement since the head is clamped to the mask on the desktop device.

What has therefore been described is a desktop system for cognitive performance which is portable and is exceptionally inexpensive and yet provides sufficient accuracy and precision to be useful in clinical drug analysis.

The Smooth Pursuit Paradigm for Clinical Drug Testing

What is now described in FIG. 11, is the Neuro-Pharmaceutical Product Development Process and Pipeline utilizing cognitive performance as measured using the smooth pursuit paradigm.

Here it can be seen that the cognitive assessment is based on a baseline-drug free environment as illustrated at 250. Thereafter the drug or clinical component is administered to the test subject as illustrated at 252 and cognitive assessment is made after drug administration as illustrated at 254. The results are compared between the baseline readings before and after drug administration at 256 to determine if the drug affects cognitive function or behavior as illustrated at 258.

The cognitive effect 260 is ascertained at 260 to be positive or negative as illustrated at 262. If there is a positive cognitive effect as illustrated at 264 then clinical trial testing may proceed as illustrated at 266.

On the other hand if there is no cognitive effect as illustrated at 268 then it is prudent to discontinue further product drug development as illustrated at 270.

Thus, the first test is whether or not an administered drug or compound has any effect on the cognitive processes for the test individual. The subject system permits a quick test of whether or not a drug or compound is at all useful for clinical purposes.

As to the cognitive assessment useful in the process in FIG. 11 and referring now to FIG. 12 the test is administered as illustrated at 280. The test includes presenting a test subject with an icon, target or dot travelling along a curvilinear path 282 with or without manual smooth pursuit feedback as illustrated at 284. Manual feedback in general involves an individual moving one's hand to touch a moving dot. Note, smooth pursuit eye tracking may be utilized without a manual component.

The smooth pursuit testing paradigm is illustrated at 290 in which the result of trying to follow an icon on a curvilinear path is ascertained. The smooth pursuit testing paradigm may include an opto-cognitive paradigm 292 which relates to the type of eye tracking 294 achievable of for instance by the desktop system described above.

The smooth pursuit testing paradigm may also include a mechanical smooth pursuit paradigm 296 including a mechanical input 298. This is the same type of mechanical or smooth pursuit that is envisioned when one uses one's finger to trace a path on a screen occupied by the moving icon.

Finally, as illustrated at 300 a hybrid smooth pursuit paradigm may be employed employing both eye tracking and mechanical input as illustrated at 302.

In one embodiment smooth pursuit testing 290 includes a smooth pursuit eye movement paradigm at 302 which involves for instance a calibration step 304, a target acquisition step 306 and a saccading test 308. This type of test procedure is described hereinbefore in connection with the desktop eye tracking apparatus.

As seen at 310, data cleansing is performed. This data cleansing can include cleansing a data file 312 utilizing filtration methods 314 that include both a normalization technique 316 and a noise infiltration detection technique 318.

After data cleaning, cognitive metrics are applied to the data as illustrated at 320. The cognitive metrics include data analysis methods 322 that in turn include anticipatory timing 324, variability metric 326, a regularity metric 328, a predictability metric 330 and a peak performance metric 332. The mathematical definitions of these metrics are presented below:

Anticipatory Timing:

$f\left(f\right)=\frac{1}{N}\sum _{j=1}^N\left(\sum _{i=1}^N{\left(t-i\right)}_{\mathrm{ij}}-\sum _{i=1}^N{\left(t-i\right)}_i\right)$ The standard deviation of the sum of the absolute value of a set of target position arrays subtracted from a set of user position arrays.N=The length of the target position (the number of elements in the array).j=The standard deviation index for the absolute value target minus user arrayi=The index for the sum of absolute value target minus user arrayt=Target position arrays.i=User position arrays.Variability:

$f\left(e\right)=\frac{1}{N^2}\sum _{k=1}^N{\left(\sum _{j=1}^N{\left({\left(d_t-d_i\right)}_j-\left(d_t\overline{-}{d}_i\right)\right)}_k-\sum _{j=1}^N\left({\left(d_t-d_i\right)}_j-\left(d_t\overline{-}{d}_i\right)\right)\right)}^2$ The variance of the standard deviation of a set of target position arrays subtracted from a set of user position arrays.N=The length of the target position (the number of elements in the array).j=The standard deviation index.k=The variance index.dt=Target distance arrays.di=User distance arrays.Regularity:

$f\left(e\right)=\mathrm{Minimum}\left[\underset{t=0}{\stackrel{t=f}{\delta }}\left(\sum _{i=0}^{i-N}e\right)\right]$ Finding the minimum of the application of the sum of an error array on a delta distribution.e=Error array.N=The length of the target position (the number of elements in the array).t=Time.i=Index of error array.Predictability:f(t+1)=kf(t_-n,t₀)A factor of k applied to any function listed on this sheet.k=Arbitrary constant.t=Input elements to any function f.Peak Performance:f(p)=Maximum[scores[t₀:t_f]]The maximum value of any indexed portion of the scores array.to=Beginning index.tf=Ending index

Thereafter as illustrated at 334 the results or a score calculation are displayed at 336.

As mentioned hereinbefore it is part and parcel of the subject invention that an extremely accurate cognitive assessment method needs to be utilized in order for one to be able to detect the efficacy or toxicity of a particular drug or compound. The use of any of the techniques including anticipatory timing, variability, regularity, predictability of peak performance may be used singly or in combination to accurately hone in on any effects of the drug or compound on the individual taking the test. This means that whatever baseline database is established, the variance from this baseline readily provides a first indicator of the ability of the administered drug or component to affect the body. If there is any effect the drug can be selected for further evaluation. If the drug or compound has no effect on cognitive performance, then it can be assumed that there will be no drug efficacy whatsoever. It can also show that there will be no toxicity.

Having ascertained that there is a cognitive performance enhancement or deprivation due to the administration of the compound or the drug, then one can utilize the correlation between anticipatory timing, variability, regularity, predictability, or peak performance and a particular disease or condition to ascertain with particularity the efficacy of the drug, or for instance any toxicity that may accompany the administration of the drug.

In summary, what is described is the utilization of smooth pursuit paradigms to ascertain cognitive performance as a measure of drug efficacy or toxicity for use as a screening tool and also to quantify the effect of the drug on the individual taking the test.

While the present invention has been described in connection with the preferred embodiments of the various figures, it is to be understood that other similar embodiments may be used or modifications or additions may be made to the described embodiment for performing the same function of the present invention without deviating therefrom. Therefore, the present invention should not be limited to any single embodiment, but rather construed in breadth and scope in accordance with the recitation of the appended claims.

Claims

1. A method for conducting pharmaceutical drug testing to ascertain the efficacy or toxicity of a candidate target drug comprising the steps of: administering the target drug to a test subject and,measuring the reaction of the test subject to the administration of the target drug utilizing smooth pursuit cognitive testing, wherein the smooth pursuit cognitive testing includes: presenting a smoothly moving object on a screen;using one or more cameras to detect gaze direction of one or more eyes of the test subject while the test subject visually tracks the smoothly moving object presented on the screen, anddetermining cognitive performance of the test subject in accordance with the test subject's performance in visually tracking the smoothly moving object presented on the screen.

2. The method of claim 1, and further including utilizing smooth pursuit cognitive testing prior to the introduction of the target drug into the test subject and determining a baseline therefrom.

3. The method of claim 2, wherein the smooth pursuit cognitive testing done after the introduction of the drug is compared to the baseline to determine if the drug has affected cognitive function or behavior.

4. The method of claim 3, wherein if cognitive function or behavior has been affected, clinical trial testing continues and wherein if no cognitive function or behavior affect has been determined, further product development of the drug is discontinued.

5. The method of claim 1, wherein presenting a smoothly moving object on a screen comprises presenting the moving object on a curvilinear path.

6. The method of claim 1, wherein the smooth pursuit cognitive testing includes calibration, target acquisition and a saccading test.

7. The method of claim 1, wherein the smooth pursuit cognitive testing includes a data cleansing step.

8. The method of claim 7, wherein the data cleansing step includes a filtration step that includes noise filtration and eliminates outlying data.

9. The method of claim 1, wherein the smooth pursuit cognitive testing includes cognitive metrics and data analysis that includes one of anticipatory timing, variability, regularity, predictability and peak performance.

10. The method of claim 9, wherein the cognitive metrics include a combination of two or more of anticipatory timing, variability, regularity, predictability and peak performance.

11. The method of claim 1, wherein the drug testing includes testing of a compound.

12. The method of claim 11, wherein the compound includes vitamins and non-drug classified substances.

13. A method of clinical drug testing, comprising the steps of: providing a portable unit for performing an eye tracking function in which an individual is asked to peer into the unit and to visually track an icon moving on a screen within the unit; and,performing a smooth pursuit cognitive testing procedure to determine the affect of any administered target drug on the behavior of a test taking subject, wherein performing the smooth pursuit cognitive testing procedure includes: presenting the moving icon on the screen within the unit;using one or more cameras, located within the unit, to detect gaze direction of one or more eyes of the test taking subject while the test taking subject visually tracks the moving icon presented on the screen within the unit, anddetermining cognitive performance of the test subject in accordance with the test taking subject's performance in visually tracking the moving icon presented on the screen.

14. The method of claim 13, wherein if it is determined that the target drug has no effect on cognitive function or behavior on the test taking subject, then clinical drug testing for the target drug is discontinued.

15. The method of claim 14, wherein if it is determined that the target drug affects cognitive function or behavior of the test taking subject, then the effect in terms of test results is measured against a baseline previously established for the test taking subject.

16. The method of claim 15, and further including the step of correlating the test results with a physiological condition of the test taking subject.

17. The method of claim 16, wherein the correlation is utilized to provide a measure of the efficacy of the target drug.

18. The method of claim 16, wherein the correlation is made to deleterious reactions of the test taking subject to the administration of the target drug corresponding to toxicity.

19. A method for clinical drug testing comprising the steps of: providing a mobile eye-tracking smooth pursuit cognitive testing unit;administering a target drug to a test taking subject; andin conjunction with administering the target drug to the test taking subject, monitoring cognitive function of the test taking subject utilizing the mobile unit, wherein monitoring cognitive function of the testing taking subject includes: presenting a smoothly moving object on a screen in the mobile unit;using one or more cameras, in the mobile unit, to detect gaze direction of one or more eyes of the test taking subject while the test taking subject visually tracks the smoothly moving object presented on the screen, anddetermining cognitive performance of the test taking subject in accordance with the test taking subject's performance in visually tracking the smoothly moving object presented on the screen.

20. The method of claim 19, wherein determining cognitive performance of the test taking subject includes determine one or more cognitive metrics including at least one of anticipatory timing, variability, regularity, predictability and peak performance.

21. The method of claim 20, wherein the unit includes a face mask to which the test taking subject presses his or her face, and wherein the test taking subject maintains positive pressure of his or her face against the face mask during smooth pursuit cognitive testing.